United States

Codexis appoints David O’Toole as CFO

Wednesday, September 5, 2012 11:08 AM

Codexis, a Redwood City, Calif.-based developer of cost-advantaged processes for the production of biofuels, bio-based chemicals and pharmaceuticals, has appointed David O’Toole as senior vice president and CFO.

More... »

Allergan opens NJ facility

Tuesday, September 4, 2012 12:39 PM

Irvine, Calif.-based Allergan has opened its first large facility in New Jersey, the R&D Center in Bridgewater, N.J.

More... »

Soligenix reports positive phase Ib results with Ricin toxin vaccine

Tuesday, September 4, 2012 08:43 AM

Soligenix, a development stage biopharmaceutical company based in Princeton, N.J., released results of a phase Ib trial of an aluminum hydroxide (Alum) adjuvanted formulation of RiVax, designed to improve the immunogenicity of the vaccine.

More... »

FDA approves first drug formulated for children with rare brain tumor

Monday, September 3, 2012 08:25 AM

The FDA has approved Novartis’ Afinitor Disperz (everolimus tablets for oral suspension), a new pediatric dosage form of the anti-cancer drug Afinitor used to treat subependymal giant cell astrocytoma (SEGA, a rare brain tumor).

More... »

Sophiris' transrectal injection of PRX302 for enlarged prostate well tolerated

Monday, September 3, 2012 08:16 AM

Sophiris Bio, a urology company based in La Jolla, Calif., released data from its transrectal safety study, in which PRX302, the company's drug candidate for the treatment of benign prostatic hyperplasia (BPH or enlarged prostate), was well tolerated through three months following a transrectal injection.

More... »

Galectin to relocate headquarters to Atlanta

Friday, August 31, 2012 01:28 PM

Galectin Therapeutics, a developer of therapeutics that target galectin proteins to treat fibrosis and cancer, will be relocating its corporate offices to Atlanta, Ga., effective October 1, 2012, while maintaining a laboratory-based effort in the Boston area.

More... »

Bayer submits NDA for regorafenib for gastrointestinal stromal tumors

Friday, August 31, 2012 12:02 PM

Bayer HealthCare and Onyx Pharmaceuticals, a global biopharmaceutical company based in San Francisco, have submitted a New Drug Application (NDA) to the FDA for the oral multi-kinase inhibitor regorafenib for the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST) in patients whose disease has progressed despite prior treatment.

More... »

Arrowhead completes enrollment in phase 1b trial of CALAA-01 in solid tumors

Friday, August 31, 2012 09:48 AM

Through its Calando Pharmaceuticals subsidiary, Arrowhead Research, a clinical stage targeted therapeutics company based in Pasadena, Calif., has completed enrollment of a phase 1b clinical trial of CALAA-01, its RNAi therapeutic candidate targeting solid tumors.

More... »

Actinium Pharmaceuticals strengthens management team

Thursday, August 30, 2012 02:44 PM

Actinium Pharmaceuticals (API), a private biopharmaceutical company in New York that develops innovative targeted radio-immunotherapeutics, has strengthened its management team with the appointment of Jack V. Talley as president and CEO and Enza Guagenti as CFO.

More... »

Aerpio completes $27M Series A Financing for diabetic macular edema

Thursday, August 30, 2012 02:07 PM

Aerpio Therapeutics, a clinical-stage biopharmaceutical spin off of Akebia Therapeutics based in Cincinnati, Ohio, has closed a $27 million Series A financing.

More... »